Ipsen: Portfolio Expansion Adds Value as Somatuline Faces Generic Pressure

Ipsen completed its acquisition of Memo Therapeutics, which added potravitug, a phase 2 rare-disease therapy. Ipsen is also on track to close its acquisition of Kartos Therapeutics, which will add navtemadlin, a phase 3 candidate for myelofibrosis.